Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma (RAD001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00933374
Recruitment Status : Terminated (delayed recruitment)
First Posted : July 7, 2009
Last Update Posted : March 18, 2015
Information provided by (Responsible Party):
Heinrich-Heine University, Duesseldorf

July 3, 2009
July 7, 2009
March 18, 2015
July 2009
January 2013   (Final data collection date for primary outcome measure)
Response rate [ Time Frame: 3 years ]
Same as current
Complete list of historical versions of study NCT00933374 on Archive Site
  • Duration of response [ Time Frame: from first determination of response until progression ]
  • Progression free survival [ Time Frame: 3 years ]
  • overall survival [ Time Frame: 3 years ]
  • safety profile of combination RAD001 and paclitaxel [ Time Frame: 6 month ]
Same as current
Not Provided
Not Provided
Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma
A Single Arm, Multi-center Phase II Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma After Failure of Prior Platin-based Chemotherapy
This is a single arm open- label phase II- trial evaluating safety and efficacy of paclitaxel and RAD001 in patients with metastatic urothelial bladder cancer who failed prior platin-based systemic therapy.

The screening phase for checking eligibility and evaluation of the patient prior start of study treatment will last up to 21 days.Tumor histology must be predominant urothelial carcinoma and confirmed histological or cytological.Patients who meet the inclusion criteria will be treated with paclitaxel 175 mg/m2 every 3 weeks and RAD001 10 mg once daily. Each cycle will use the combination of paclitaxel 175 mg/m2 3-weekly with RAD001 10 mg daily starting at day 1 of a 21 days treatment cycle. Additional visits after day 1 are performed at day 8 and day 15 of each cycle Assessment of safety and toxicity will be performed at every visit.

Patients will be treated until no signs of clinical or radiological progression are evident and the study treatment is well tolerated for a maximum of 6 cycles.

Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Bladder Cancer
  • Drug: paclitaxel
    Paclitaxel (175 mg/m3)will be administered as a 3 hour continuous IV infusion after standard premedication every 3 weeks
    Other Name: Taxol
  • Drug: RAD001
    10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
    Other Name: Certican, Everolimus
Experimental: Paclitaxel and RAD001
175 mg /m3 paclitaxel every 3 weeks and 10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
  • Drug: paclitaxel
  • Drug: RAD001
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
September 2013
January 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with histologically proven carcinoma of the urinary tract including urinary bladder, ureter, renal pelvis and lower urinary tract. Urothelial carcinoma should be the predominant histology
  • Confirmation of locally relapsed or metastatic disease by imaging. Measurable disease according to RECIST- guidelines with ≥1 measurable lesion has to be evident.
  • If bone is the only metastatic site a quantification of the target lesion(s) using MRI is mandatory.
  • Failure of prior platin- based chemotherapy
  • Patients may have shown progressive disease within the first 3 months of platin-based chemotherapy (primary failure) or progression within 3 months after the end of platin-based chemotherapy (early relapse)-Prior therapy with ≤ 4 chemotherapeutic drugs
  • Patients with tumor relapse within 3 months after cystectomy in the neoadjuvant or adjuvant setting are not eligible.
  • ECOG performance status 0-2
  • Adequate haematological, liver and renal functions.

    • Neutrophil count > 1500/mm3, haemoglobin > 9 g/dl, platelets ≥ 100.000/ mm3
    • Serum bilirubin ≤ 1.5 x ULN, ALT and AST ≤ 2.5x ULN. Patients with known liver metastases who have an AST and ALT ≤ 5x ULN.
    • serum creatinine ≤ 2 x ULN.
  • Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days prior to the first dose of study drug. Female subjects of childbearing potential must be using two acceptable methods of contraception, from the time of screening and for the duration of the study, through study completion and for 3 months following study completion
  • Age > 18 years.
  • Able to communicate well with the investigator, to understand and comply with the requirements of the study. Understand and sign the written informed consent.
  • Patients must give written informed consent
  • No concurrent treatment with other experimental drugs or anti-cancer drugs
  • Another distinguishable malignancy will be permitted

Exclusion Criteria:

  • chemotherapy, radiation therapy or any other anticancer therapy within 4 weeks of the first dose of study drug.
  • Participation in any clinical investigation within 4 weeks prior to initial dosing.
  • known hypersensitivity to RAD001 or other rapamycin analogs and paclitaxel or other taxanes, or to its excipients.
  • previously received RAD001, other mTOR inhibitors or taxanes or epothilones
  • known metastasis of central nervous system.
  • symptomatic pleural effusions or symptomatic ascites.
  • wide field radiation therapy to up to ≥ 25% of the bone marrow within 4 weeks prior therapy.
  • intravenous radionuclide therapy, e.g. phosphorus (32P), strontium (89SrCl), rhenium (186Re)or samarium (153Sm).
  • Patients who have undergone major surgery within 4 weeks prior to starting study drug,open biopsy, or significant traumatic injury, or who have not recovered from the side effects of any of the above.
  • Chronic systemic treatment with corticosteroids corresponding to a prednisone equivalent of > 10 mg daily. Patients receiving corticosteroids must be on a stable dose for ≥ 4 weeks prior to the first dose of RAD001. Topical or inhaled corticosteroids are permitted.
  • Concomitant medication with strong CYP3A4- inhibitors or CYP3A4- inducers.
  • active bleeding diathesis.
  • Neuropathy > grade 1.
  • any severe and/or uncontrolled medical conditions(unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤ 6 months, serious uncontrolled cardiac arrhythmia, uncontrolled hyperlipidemia, active or uncontrolled severe infection,cirrhosis,chronic or persistent active hepatitis)
  • severely impaired lung function as defined as spirometry and DLCO that is 50% of the normal predicted value and/or O2 saturation ≤ 88% at rest on room air
  • Uncontrolled diabetes
  • Hepatic impairment with a Child-Pugh score >9
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Heinrich-Heine University, Duesseldorf
Heinrich-Heine University, Duesseldorf
Not Provided
Principal Investigator: Peter Albers, Professor Heinrich-Heine-University, Department of Urology
Heinrich-Heine University, Duesseldorf
March 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP